Long $NSPH for .40's and beyond
NSPH has moderate negative correlation with larger NASX biotech's. BIB charts implying corrective phase coming. NSPH is a beaten down stock with good risk-reward here and I believe Verigene System (FDA cleared) could be game-changer for Nanosphere.
A few excerpts from finance.yahoo.com/news/scripps-study-illustrates-clinical-economic-120000635.html :
"The statistically significant findings included a 25.7 hour reduction in time to targeted therapy (61.1 versus 35.4 hours), a 1.9 day median reduction in length of stay (9.1 versus 7.2 days) and $7,240 reduction in median hospital costs per patient ($17,530 versus $10,290)."
''A majority of health care in the U.S. is provided in community-based hospitals. These study findings demonstrate the profound impact on patient care and hospital costs the Verigene System can deliver to a wide spectrum of health care settings,' said Michael McGarrity, Nanosphere's president and chief executive officer."
A few excerpts from finance.yahoo.com/news/scripps-study-illustrates-clinical-economic-120000635.html :
"The statistically significant findings included a 25.7 hour reduction in time to targeted therapy (61.1 versus 35.4 hours), a 1.9 day median reduction in length of stay (9.1 versus 7.2 days) and $7,240 reduction in median hospital costs per patient ($17,530 versus $10,290)."
''A majority of health care in the U.S. is provided in community-based hospitals. These study findings demonstrate the profound impact on patient care and hospital costs the Verigene System can deliver to a wide spectrum of health care settings,' said Michael McGarrity, Nanosphere's president and chief executive officer."
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.